| Patents for C07C 233 - Carboxylic acid amides (28,881) |
|---|
| 08/13/2008 | CN101239993A Transition metal complex having diphosphine compound as ligand |
| 08/13/2008 | CN101239992A Transition metal complex having diphosphine compound as ligand |
| 08/13/2008 | CN101239991A Transition metal complex having diphosphine compound as ligand |
| 08/13/2008 | CN101239928A Propanoic derivatives for treating lipid metabolism disorder |
| 08/13/2008 | CN101239927A Method for preparing monomer of temperature-sensitive polyisopropylacrylamide |
| 08/13/2008 | CN100410236C Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) |
| 08/13/2008 | CN100410235C Capsicine chemical synthesis and purification method |
| 08/13/2008 | CN100409844C Noval compound, its synthetizing process and therapeutic use |
| 08/12/2008 | US7411100 Process for the preparation of ring compounds |
| 08/12/2008 | US7411091 e.g. N-2- (4-Butyloxy-benzylamino)-ethyl-acetamide; sodium or calcium channel modulators; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases |
| 08/12/2008 | US7411089 Dissolving in solvent in which nateglinide is highly soluble such as ethanol, dioxane, dichloromethane, or acetone; adding water or hexane in which nateglinide is not soluble; crystallization |
| 08/12/2008 | US7411072 e.g. 5-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-3H-benzooxazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia, Crohn's disease |
| 08/12/2008 | US7411031 Synthesis of polyanhydrides |
| 08/12/2008 | CA2322158C Arylphenyl-substituted cyclic keto-enols |
| 08/07/2008 | WO2008094503A2 Glycerol ester-free functionalized vegetable oil derivatives and their latex compositions |
| 08/07/2008 | WO2008093655A1 Polyalcohol compound and pharmaceutical agent |
| 08/07/2008 | WO2008092955A1 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
| 08/07/2008 | WO2008070111A3 Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
| 08/07/2008 | WO2008068600A3 An improved process for the preparation of zaleplo |
| 08/07/2008 | US20080188654 Compounds for treatment of inflammation, diabetes and related disorders |
| 08/07/2008 | US20080188566 Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning |
| 08/07/2008 | US20080188565 Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning |
| 08/07/2008 | US20080188561 N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| 08/07/2008 | US20080188533 Dual-acting antihypertensive agents |
| 08/07/2008 | US20080188529 N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders |
| 08/07/2008 | US20080188489 Cell differentiation inducer |
| 08/07/2008 | US20080188475 Perhydro- or hydrophenanthrene derivatives; antiinflammatory, analgesic, anticarcinogenic, and antitumor agents; autoimmune, skin, cardiovascular, and viral diseases |
| 08/07/2008 | US20080187567 N-substituted monomers and polymers |
| 08/07/2008 | CA2677173A1 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
| 08/06/2008 | EP1951769A1 Polymer having sulfonic acid group or sulfonic acid ester group and amide group, and toner for developing electrostatic latent image having the polymer |
| 08/06/2008 | EP1951701A2 Ep2 receptor agonists |
| 08/06/2008 | EP1951690A1 Heterocyclic cetp inhibitors |
| 08/06/2008 | EP1951663A2 (r)-arylkylamino derivatives and pharmaceutical compositions containing them |
| 08/06/2008 | EP1951658A1 Glucagon receptor antagonists, preparation and therapeutic uses |
| 08/06/2008 | EP1951657A1 Process for the manufacture of iohexol |
| 08/06/2008 | EP1951656A1 Histone deacetylase inhibitors as therapeutics for neurological diseases |
| 08/06/2008 | EP1951381A1 Novel lipophobic perfluoroalkyl polyamides, preparation thereof and use thereof |
| 08/06/2008 | EP1397341B1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 08/06/2008 | EP1311475B1 Aminocyclohexane derivatives |
| 08/06/2008 | EP1133284B2 A process for the preparation of crystalline particles |
| 08/06/2008 | EP1120391B1 Molecular compounds containing novel carboxylic acid derivatives as the constituent compound |
| 08/06/2008 | CN101238093A Process for producing high-purity N-vinylcarboxamides |
| 08/06/2008 | CN101234994A Ionic liquid formed by dimethylamide and thiocyanate and its preparation method and application |
| 08/06/2008 | CN100408553C Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate of the same |
| 08/05/2008 | US7408008 Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support |
| 08/05/2008 | US7407917 Oil additive compound is the reaction product of a linear or branched, saturated or unsaturated monovalent aliphatic acid having 8 to 22 carbon atoms, urea, and polyalkylenepolyamine; non-borated and/or borated; reducing shudder in internal combustion engines; high torque transmissive capacity |
| 08/05/2008 | US7407910 Ligands for asymmetric reactions |
| 08/05/2008 | CA2418054C Inhibitors of .alpha.4 mediated cell adhesion |
| 08/05/2008 | CA2388470C Use of carbonylamino derivatives against cns disorders |
| 07/31/2008 | WO2008091967A1 Chemical compounds |
| 07/31/2008 | US20080183003 Neuroprotective agents; nitrate-functional, for example 1-amino-3,5-dimethyl-7-nitrateadamantane hydrochloride |
| 07/31/2008 | US20080182881 TNF-alpha production inhibitors |
| 07/30/2008 | EP1950213A2 Process for the synthesis of N-[3- (3-cyanopyrazolo [1,5a] pyrimidin-7-yl) -phnyl] -N-ethyl-acetamide |
| 07/30/2008 | EP1949000A2 Resorbable phenolic polymers |
| 07/30/2008 | EP1948592A1 Organic compounds |
| 07/30/2008 | EP1572624B1 Method for producing light coloured polyalkylene glycol diethyl ether of fatty acid alcanolamine |
| 07/30/2008 | CN101230008A Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| 07/30/2008 | CN100406432C Process of extracting capsicine crystal from chili |
| 07/30/2008 | CN100406007C Asthma and allergic inflammation modulators |
| 07/29/2008 | US7405331 High-purity (fluoroalkyl)benzene derivative and process for producing the same |
| 07/29/2008 | US7405324 chemical preparing acetamido adamantanes intermediate first from halogen adamantane, use for making N-methyl-D-aspartic acid (NDMA) receptor antagonist, treating Parkinson's Disease, central nervous system disorders |
| 07/29/2008 | US7405323 Invention provides five novel polymorphic forms of modafinil racemate called CRL 40476 form III, CRL 40476 form IV, CRL 40476 form V, CRL 40476 form VI, CRL 40476 form VII; preparing a new solvate of modafinil comprising dissolving in solvent and crystallizing; sleep disorders |
| 07/29/2008 | US7405307 N-(p-(2-alpha-carboxybenzylamino)ethylamino)phenyl)p-(p-trifluoromethylphenyl)benzamide; antiobesity and anti-type II diabetic agents |
| 07/29/2008 | US7405065 Such as 1S,4R)-1-amino-4-(hydroxymethyl)-2-cyclopentene via N-acetylamino-alcohol hydrolase isolated from Rhodococcus, Gordona, Arthrobacter, Alcaligenes, Agrobacterium/Rhizobium, Bacillus, Pseudomonas or Alcaligenes/Bordetella |
| 07/29/2008 | US7404912 Salicylamide-lanthanide complexes for use as luminescent markers |
| 07/29/2008 | CA2371857C Gardos channel antagonists |
| 07/29/2008 | CA2214323C Compounds and compositions for delivering active agents |
| 07/29/2008 | CA2203033C Compounds and compositions for delivering active agents |
| 07/24/2008 | WO2008088540A2 N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
| 07/24/2008 | WO2008087514A2 Hdac inhibitors |
| 07/24/2008 | US20080177108 the one radiochemical step synthesis of [18F] N-(5-Fluoro-2-phenoxyphenyl)-N-(2-(2-[18F]fluoroethoxy)-5-methoxybenzyl)acetamide; benzodiazepine receptor ligand; neuroprotectant; neurodegenerative diseases diagnostic; one radiochemical step synthesis of 18F; easy purified by-products |
| 07/24/2008 | US20080177102 may be coated on or incorporated within bulk materials, which may then be subsequently utilized to fabricate a radiopaque medical device; may be produced in various forms such as a dendrimer and/or incorporated as the end groups of polymeric chain |
| 07/24/2008 | US20080176952 Management of Ophthalmologic Disorders, Including Macular Degeneration |
| 07/24/2008 | US20080176945 e.g. 1-methyl-cyclohexanecarboxylic acid (3-methoxy-phenyl)-amide; topical products, oral care products, nasal care products, toilet articles, ingestible products and chewing gum |
| 07/24/2008 | US20080176807 Facially amphiphilic polymers and oligomers and uses thereof |
| 07/24/2008 | US20080175795 e.g. 3-{4-[4-(2-amino-2-carbamoyl-ethyl)-phenoxy]-phenyl)-propionic acid; antiinflammatory and immunological diseases, cytokines (TNF- alpha , IL-1, IL-6), orexin, nitric oxide synthase inhibitor; obesity, hyperlipidemia, migraine, asthma, chronic obstructive pulmonary disease, osteoarthritis |
| 07/24/2008 | DE102007002797A1 Verwendung von mit schmelzbaren Materialien gefüllte Hohlkörper als Latentwärmespeicher Using filled with meltable materials hollow body as latent heat storage |
| 07/24/2008 | DE102007002796A1 Verwendung von Amid-Verbindungen zur Speicherung von latenter Wärme Use of amide compounds for storage of latent heat |
| 07/24/2008 | CA2673586A1 N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
| 07/23/2008 | EP1945621A1 Process to prepare amino acid derivatives |
| 07/23/2008 | EP1945241A2 Treatment of proliferative disorders withpolycationic agents |
| 07/23/2008 | EP1735267B1 Aminoalkyl substituted esters and amides of fumaric acid for neutralising malodor |
| 07/23/2008 | EP1587506B1 Administration of capsaicinoids |
| 07/23/2008 | EP1487781B1 Process for preparing 2-aminoindan derivatives |
| 07/23/2008 | EP1071680B1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 07/23/2008 | CN101228125A Cathepsin K inhibitors |
| 07/23/2008 | CN101228116A Benzoyl-substituted serineamides |
| 07/23/2008 | CN101228115A Bis-aromatic amides and their uses as sweet flavor modifiers, tastants and taste enhancers |
| 07/23/2008 | CN101225053A Preparation method of anti-oxidizing agent |
| 07/23/2008 | CN101225052A Process for extracting and separating capsaicin, capsicum red pigment and capsicum oleoresin crude product from red pepper |
| 07/22/2008 | US7402697 Antibacterial agents |
| 07/22/2008 | US7402696 exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hyperten |
| 07/22/2008 | CA2343346C Process for the preparation of 4,5-diamino shikimic acid derivatives |
| 07/22/2008 | CA2313638C Cyclohexene carboxylates as neuraminidase inhibitors |
| 07/17/2008 | US20080171881 Method for Producing Organic Compound and Method for Decomposing Compound Having Dicarboximide Skeleton |
| 07/17/2008 | US20080171788 N-(diaminomethylene)-9H-fluorene-2-carboxamide derivatives; dual antagonist for 5-HT2B and 5-HT7 receptors having selective binding affinities for 5-HT2B and 5-HT7 receptors; side effect reduction, nontoxic |
| 07/17/2008 | US20080171786 Substituted [(Phenylethanoyl)Amino]Benzamides |
| 07/17/2008 | US20080171692 Substituted amides |
| 07/17/2008 | US20080171681 3-(2-hydroxyphenyl)-2-propenamides that react to form a lactone and an amine; laundry detergents, perfumes, shampoos and hair conditioners |
| 07/17/2008 | US20080171004 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives |